ApolloMed And Helynx To Present Results Of Predictive Analytics Study At The 13th Annual MIT Sloan Health & BioInnovations Conference
GLENDALE, Calif., Feb. 25, 2016 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed" or "the Company") (OTC: AMEH), an integrated population health management company, and Helynx, Inc., a technology company that has developed a next-generation platform for machine learning and predictive analytics, today announced that they will present the results of a study based on ApolloMed Accountable Care Organization ("ACO") patients at the 13th Annual MIT Sloan Health & BioInnovations Conference on Friday, February 26 at the MIT Media Lab in Cambridge, Massachusetts.
The theme of this year's conference is "Strategic Analytics: Changing the Future of Healthcare" and will highlight the latest trends in Big Data uses within healthcare. Collecting and analyzing enormous amounts of healthcare data enables clinical providers to improve patient care and medical management processes across the whole healthcare value chain. The study, "Predicting Admissions and Emergency Department Visits from Time-Lagged ACO-Specific Data" was performed by evaluating three years of de-identified claims data on nearly 30,000 ApolloMed ACO Medicare patients using Helynx's analytics engine. Helynx implemented a large scale multivariate computational model based on all available data. Even constrained by 60- to 90-day old claims data, the multivariate predictor outperformed traditional methods in early identification of at-risk patients.
The study was carried out by Chess Stetson, Ph.D, Boris Revechkis, Ph.D and Kris Chaisanguanthum, Ph.D from Helynx and Diane Pham, M.D. from ApolloMed.
"We are very pleased with our collaboration with Helynx," stated Warren Hosseinion, MD, Chief Executive Officer of Apollo Medical Holdings. "More accurately predicting patient admissions and emergency department visits can trigger actions to improve health outcomes and reduce expenditures. ApolloMed will continue to be at the forefront of delivering next generation value-based care."
"Our goal is to help ApolloMed prevent avoidable adverse outcomes for their patients," stated Chess Stetson, Ph.D., Chief Executive Officer of Helynx, Inc. "ApolloMed clinical staff could use this newly discovered predictive information to identify at-risk patients even sooner."
About Apollo Medical Holdings, Inc.
Headquartered in Glendale, California, ApolloMed is an integrated population health management company committed to providing exceptional multi-disciplinary care in the communities it serves. ApolloMed is addressing the healthcare needs of its patients by leveraging its integrated healthcare delivery platform comprised of six affiliated and complementary physician groups: ApolloMed Hospitalists, ApolloMed ACO (Accountable Care Organization), Maverick Medical Group (Independent Physician Association), ApolloMed Care Clinics, Apollo Care Connect and Apollo Palliative Services. ApolloMed strives to improve medical outcomes with high-quality, cost-efficient care. For more information, please visit www.apollomed.net
Forward Looking Statements
This press release may contain forward-looking statements, including information about management's view of future expectations, plans and prospects for Apollo Medical Holdings, Inc. ("the Company"). In particular, when used in the preceding discussion, the words "predicts," "believes," "expects," "intends," "seeks," "estimates," "plans," "anticipates," and similar conditional expressions or future or conditional verbs such as "will," "may," "might," "should," "would" and "could" are intended to identify forward-looking statements. In addition, our representatives may from time to time make oral forward-looking statements. Any such statements, other than those of historical fact, about an action, event or development, are forward-looking statements. Such statements are based on the current expectations and certain assumptions of the Company's management. Such statements are, therefore, subject to a variety of known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company, which could cause the actual results, performance or achievements of the Company, its subsidiaries and concepts to be materially different than those that may be expressed or implied in such statements or anticipated on the basis of historical trends. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company's actual results, performance or achievements may vary materially from those described in the relevant forward-looking statement as being expected, anticipated, intended, planned, believed, sought, estimated or projected. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included herein are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update or revise these forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statement was made, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. You should not place undue reliance on any forward-looking statement and should consider the uncertainties and risks discussed under Item 1A. "Risk Factors" of the Company's Annual Report on Form 10-K for the year ended March 31, 2015 and in any of the Company's other subsequent Securities and Exchange Commission filings.
FOR ADDITIONAL INFORMATION
Apollo Medical Management
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/apollomed-and-helynx-to-present-results-of-predictive-analytics-study-at-the-13th-annual-mit-sloan-health--bioinnovations-conference-300226503.html
SOURCE Apollo Medical Holdings, Inc.